Article Text

PDF
Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab
  1. Savino Sciascia,
  2. Elena Rubini,
  3. Massimo Radin,
  4. Irene Cecchi,
  5. Daniela Rossi,
  6. Dario Roccatello
  1. Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Turin, Italy
  1. Correspondence to Dr Savino Sciascia, Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Turin 10154, Italy; savino.sciascia{at}unito.it

Statistics from Altmetric.com

The current management of antiphospholipid syndrome (APS) centres on attenuating the procoagulant state while balancing the haemorrhagic risks.1 This approach relies mainly on a thromboprophylaxis strategy rather than targeting pathogenic antiphospholipid antibodies (aPL)-mediated pathways.

Herewith, we report the aPL disappearance in three patients with APS associated to systemic lupus erythematous (SLE) while on treatment with belimumab, potentially paving the way for development of new targeted therapies for APS. Belimumab is a monoclonal antibody that works by blocking the B-lymphocyte stimulator and avoiding B-cell activation.2 It is the first biological drug approved for the treatment of autoantibody positive SLE in active phase and it has shown its capability to reduce the antibodies levels, including anti-double stranded-DNA.3 Intriguingly, in murine models of APS in the setting of SLE, belimumab …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.